» Articles » PMID: 35561704

Clinical Features Of, and Risk Factors For, Severe or Fatal COVID-19 Among People Living with HIV Admitted to Hospital: Analysis of Data from the WHO Global Clinical Platform of COVID-19

Overview
Journal Lancet HIV
Date 2022 May 13
PMID 35561704
Authors
Affiliations
Soon will be listed here.
Abstract

Background: WHO has established a Global Clinical Platform for the clinical characterisation of COVID-19 among hospitalised individuals. We assessed whether people living with HIV hospitalised with COVID-19 had increased odds of severe presentation and of in-hospital mortality compared with individuals who were HIV-negative and associated risk factors.

Methods: Between Jan 1, 2020, and July 1, 2021, anonymised individual-level data from 338 566 patients in 38 countries were reported to WHO. Using the Platform pooled dataset, we performed descriptive statistics and regression analyses to compare outcomes in the two populations and identify risk factors.

Findings: Of 197 479 patients reporting HIV status, 16 955 (8·6%) were people living with HIV. 16 283 (96.0%) of the 16 955 people living with HIV were from Africa; 10 603 (62·9%) were female and 6271 (37·1%) were male; the mean age was 45·5 years (SD 13·7); 6339 (38·3%) were admitted to hospital with severe illness; and 3913 (24·3%) died in hospital. Of the 10 166 people living with HIV with known antiretroviral therapy (ART) status, 9302 (91·5%) were on ART. Compared with individuals without HIV, people living with HIV had 15% increased odds of severe presentation with COVID-19 (aOR 1·15, 95% CI 1·10-1·20) and were 38% more likely to die in hospital (aHR 1·38, 1·34-1·41). Among people living with HIV, male sex, age 45-75 years, and having chronic cardiac disease or hypertension increased the odds of severe COVID-19; male sex, age older than 18 years, having diabetes, hypertension, malignancy, tuberculosis, or chronic kidney disease increased the risk of in-hospital mortality. The use of ART or viral load suppression were associated with a reduced risk of poor outcomes; however, HIV infection remained a risk factor for severity and mortality regardless of ART and viral load suppression status.

Interpretation: In this sample of hospitalised people contributing data to the WHO Global Clinical Platform for COVID-19, HIV was an independent risk factor for both severe COVID-19 at admission and in-hospital mortality. These findings have informed WHO immunisation policy that prioritises vaccination for people living with HIV. As the results mostly reflect the data contribution from Africa, this analysis will be updated as more data from other regions become available.

Funding: None.

Translation: For the French translation of the abstract see Supplementary Materials section.

Citing Articles

Neutralizing Activity and T-Cell Responses Against Wild Type SARS-CoV-2 Virus and Omicron BA.5 Variant After Ancestral SARS-CoV-2 Vaccine Booster Dose in PLWH Receiving ART Based on CD4 T-Cell Count.

Ha N, Kim A, Jeong H, Cheon S, Park C, Choe J J Korean Med Sci. 2025; 40(9):e28.

PMID: 40065712 PMC: 11893351. DOI: 10.3346/jkms.2025.40.e28.


Perspectives of the COVID-19 pandemic and vaccination among racially and ethnically diverse gay, bisexual, and other men who have sex with men with and without HIV in the US South: findings from qualitative individual in-depth interviews.

Waldman J, Alonzo J, Mann-Jackson L, Aguilar-Palma S, Garcia M, Smart B BMC Infect Dis. 2025; 25(1):193.

PMID: 39923031 PMC: 11806891. DOI: 10.1186/s12879-025-10583-5.


Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.

Garrett N, Tapley A, Hudson A, Dadabhai S, Zhang B, Mgodi N EClinicalMedicine. 2025; 80:103054.

PMID: 39902315 PMC: 11788791. DOI: 10.1016/j.eclinm.2024.103054.


Prevalence of post-acute sequelae of SARS-CoV-2 infection in people living with HIV: a systematic review with meta-analysis.

Pouliopoulou D, Billias N, MacDermid J, Miller E, OBrien K, Quinn K EClinicalMedicine. 2025; 79():102993.

PMID: 39802304 PMC: 11721256. DOI: 10.1016/j.eclinm.2024.102993.


Factors associated with COVID-19 in-hospital death and COVID-19 vaccine effectiveness against COVID-19 hospitalization in the Philippines during pre-omicron and omicron period: A case-control study (MOTIVATE-P study).

Arashiro T, Solante R, Sayo A, Garcia R, Kris M, Suzuki S Epidemiol Infect. 2024; 153():e18.

PMID: 39703003 PMC: 11748018. DOI: 10.1017/S0950268824001845.


References
1.
So-Armah K, Benjamin L, Bloomfield G, Feinstein M, Hsue P, Njuguna B . HIV and cardiovascular disease. Lancet HIV. 2020; 7(4):e279-e293. PMC: 9346572. DOI: 10.1016/S2352-3018(20)30036-9. View

2.
Ssentongo P, Heilbrunn E, Ssentongo A, Advani S, Chinchilli V, Nunez J . Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021; 11(1):6283. PMC: 7973415. DOI: 10.1038/s41598-021-85359-3. View

3.
Hadi Y, Naqvi S, Kupec J, Sarwari A . Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study. AIDS. 2020; 34(13):F3-F8. PMC: 8407436. DOI: 10.1097/QAD.0000000000002666. View

4.
Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J . Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020; 81(2):e16-e25. PMC: 7177098. DOI: 10.1016/j.jinf.2020.04.021. View

5.
Tesoriero J, Swain C, Pierce J, Zamboni L, Wu M, Holtgrave D . COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State. JAMA Netw Open. 2021; 4(2):e2037069. PMC: 7859843. DOI: 10.1001/jamanetworkopen.2020.37069. View